Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean aromatase inhibitor?
Displaying drugs 251 - 275 of 2435 in total
Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
Approved
Matched Categories: … UGT1A1 Inhibitors ... Adrenergic Uptake Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain . Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Approved
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Neurotransmitter Uptake Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (moderate) ... Serotonin antagonist and reuptake inhibitors (SARIs) …
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Categories: … Adrenergic Uptake Inhibitors ... Norepinephrine Uptake Inhibitors ... Neurotransmitter Uptake Inhibitors ... Serotonin and Noradrenaline Reuptake Inhibitors ... Combined Inhibitors of Serotonin/Norepinephrine Reuptake …
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start...
Approved
Matched Categories: … Enzyme Inhibitors ... Glycoside Hydrolase Inhibitors
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.[A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer...
Approved
Investigational
Matched Categories: … Growth Inhibitors ... Angiogenesis Inhibitors ... Vascular Endothelial Growth Factor Inhibitors ... VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Sodium Potassium Chloride Symporter Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing...
Approved
Withdrawn
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Nucleic Acid Synthesis Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strong) …
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Categories: … Growth Inhibitors ... Angiogenesis Inhibitors
Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... 5-alpha Reductase Inhibitors ... Steroid Synthesis Inhibitors
The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses,...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors (weak) …
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (moderate) …
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Adenosine Deaminase Inhibitors ... Nucleic Acid Synthesis Inhibitors
A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Approved
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Niclosamide is an antihelminthic used for the treatment of tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms....
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible...
Approved
Matched Categories: … EGFR (Epidermal Growth Factor Receptor) inhibitors
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Protease Inhibitors ... Thrombin Inhibitors ... Serine Protease Inhibitors
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator...
Approved
Matched Categories: … Enzyme Inhibitors ... OAT3/SLC22A8 Inhibitors ... Reverse Transcriptase Inhibitors ... Nucleic Acid Synthesis Inhibitors ... Nucleoside Reverse Transcriptase Inhibitors
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Categories: … Prolactine Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
Approved
Matched Categories: … Enzyme Inhibitors ... Protein Synthesis Inhibitors
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors (moderate) ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Nucleic Acid Synthesis Inhibitors ... Reverse Transcriptase Inhibitors ... Nucleoside Reverse Transcriptase Inhibitors ... Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Categories: … OCT1 inhibitors ... OCT2 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors (strong) …
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Approved
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strong) …
Displaying drugs 251 - 275 of 2435 in total